J. Chang

Southern Taiwan University of Science and Technology — Taiwan

Medicine · Health Sciences

10h-index395citations42works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(20), Colorectal Cancer Treatments and Studies(8), Lung Cancer Research Studies(8), Lung Cancer Diagnosis and Treatment(7), Cancer Immunotherapy and Biomarkers(6)

Publications42 total

Using Integrated Chips in IoT for Health to Monitor Non-Contact Heart Rate Variability
2025
Developing A Multi-Tasks Module to Integrate Biodiversity and to Fulfill the Request of the Task Force on Nature-Related Financial Disclosures (TNFD) for Corporate Sustainability- Case Study of A Taiwan Semiconductor Company
2024
653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
Annals of Oncology·2023· 24 citedOpen Access
1370P Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Annals of Oncology·2023Open Access
592P The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Annals of Oncology·2023Open Access
P45.08 Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
Journal of Thoracic Oncology·2021· 1 citedOpen Access
LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
Annals of Oncology·2021· 6 cited
147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients
Journal of Thoracic Oncology·2021· 2 citedOpen Access
P47.01 Plasma Exosomal Long RNA in SCLC Diagnosis and Prognosis
Journal of Thoracic Oncology·2021Open Access
P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
Journal of Thoracic Oncology·2021· 7 citedOpen Access
FP14.17 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
Journal of Thoracic Oncology·2021· 3 citedOpen Access
126P A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Annals of Oncology·2020Open Access
LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
Annals of Oncology·2020· 29 cited
Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
Annals of Oncology·2020· 70 citedOpen Access
456P Tumor response to irinotecan is associated with IL-10 expression level in metastatic colorectal cancer - Results from mCRC biomarker study
Annals of Oncology·2020
JCSE01.18 A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology·2019Open Access
OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2019· 23 citedOpen Access
P1.01-66 A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology·2019
P2.09-08 Correlation Between Hormone Receptor Expression and EGFR Gene Mutation in Lung Cancer Patients with Simultaneous Primary Breast Cancer
Journal of Thoracic Oncology·2019
P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis
Journal of Thoracic Oncology·2019· 5 cited
page 1 of 3Next →

Frequent Co-authors

Yi‐Long Wu(9), J. Wang(9), Ying Cheng(8), Shun Lü(7), J. Feng(6), Hai‐Yan Tu(5), Jiuwei Cui(5), Jun Zhao(5), Jian Fang(5), Yi Hu(5), Xuan Liu(5), Xianghua Wu(5), Meiqi Shi(4), Y. Zhang(4), Hui Yu(4), C. Liu(4), L. Cao(3), Yongqian Shu(3), Yehuan Sun(3), C. Zhou(3)